The Apollo Hospitals has started offering monoclonal antibody therapy for COVID-19 patients, who have mild symptoms and comorbidities.
The therapy involves an antibody cocktail involving casirivimab and imdevimab and is intended for patients with mild and moderate COVID-19 symptoms and those who at high risk of developing severe COVID, the hospital said in a statement.
Monoclonal antibodies bind to and neutralise the SARS-CoV-2 virus. It helps in fighting the infection by resembling the natural antibodies produced when one gets infected with COVID. It thus helps strengthen the immune defence system
“We are glad to launch a pan India programme for advanced treatment, comprising neutralising monoclonal antibodies for our patients with COVID-19. We are confident this treatment option will significantly boost our efforts to bring the pandemic under control and help prevent progression of the disease in those with mild to moderate COVID-19,” said Anupam Sibal, Group Medical Director of Apollo Hospitals Group